Author(s):
Sarika Pranam Patil, Shreya Sanjay Pawar, Samarth Mallu Pattad, Aniket Dadaso Pawar, Sayali Babasaheb Pawar, Harsh Govind Pawar, Vrushabh Rajkumar Patil
Email(s):
naradesarika@gmail.com
DOI:
10.52711/2231-5691.2025.00041 
Address:
Sarika Pranam Patil, Shreya Sanjay Pawar, Samarth Mallu Pattad, Aniket Dadaso Pawar, Sayali Babasaheb Pawar, Harsh Govind Pawar, Vrushabh Rajkumar Patil
Department of Pharmaceutical Chemistry, Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digraj, Sangli, Maharashtra, 416 305, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2025
ABSTRACT:
The present study aimed to investigate the effects of co-administration of varying concentrations of curcumin (2, 6, 10, 14, and 18mg) and pretreatment at different time intervals (30, 60, and 120minutes) on the goat intestinal permeability of Granisetron. The experiments were conducted using a Franz diffusion cell in phosphate buffer at pH 7.4. Permeability data were analyzed to determine the percentage cumulative drug release (%CDR), apparent permeability coefficient (Papp), flux (J), and enhancement ratio (ER). The co-administration of curcumin with Granisetron HCl was observed to significantly reduce the membrane permeability of Granisetron HCl. Similarly, pretreatment with curcumin led to a notable decrease in Granisetron HCl permeability. These findings suggest that curcumin does not facilitate increased permeability or bioavailability of Granisetron HCl, and pretreatment with curcumin has a further detrimental effect on its membrane permeability.
Cite this article:
Sarika Pranam Patil, Shreya Sanjay Pawar, Samarth Mallu Pattad, Aniket Dadaso Pawar, Sayali Babasaheb Pawar, Harsh Govind Pawar, Vrushabh Rajkumar Patil. Assessment of the Modulatory effects of Curcumin Co-Administration and Pretreatment on Granisetron Intestinal Permeability using a Goat Membrane Model. Asian Journal of Pharmaceutical Research. 2025; 15(3):255-2. doi: 10.52711/2231-5691.2025.00041
Cite(Electronic):
Sarika Pranam Patil, Shreya Sanjay Pawar, Samarth Mallu Pattad, Aniket Dadaso Pawar, Sayali Babasaheb Pawar, Harsh Govind Pawar, Vrushabh Rajkumar Patil. Assessment of the Modulatory effects of Curcumin Co-Administration and Pretreatment on Granisetron Intestinal Permeability using a Goat Membrane Model. Asian Journal of Pharmaceutical Research. 2025; 15(3):255-2. doi: 10.52711/2231-5691.2025.00041 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2025-15-3-5
REFERENCE:
1. López-Candales A, O'Connor K, Auerbach A. Granisetron: a review of its pharmacology and clinical applications. Expert Rev Clin Pharmacol. 2011;4(3):305-14. doi:10.1586/ecp.11.16.
2. Darakjian LIA. Pharmacokinetics of granisetron: An overview of its distribution, protein binding, and role as a P-glycoprotein substrate. Pharmacotherapy. 2015; 35(10). doi:10.1002/phar.1663.
3. Bansal S, Choudhary P, Khanna A, et al. Role of bioenhancers in enhancing the bioavailability of drugs: A review. J Pharm Bioallied Sci. 2012;4(1):3-10. doi:10.4103/0975-7406.94200.
4. Tiwari G, Tiwari R, Tripathi A, et al. Bioavailability enhancers: A review. Int J Pharm Sci Rev Res. 2010; 1(1):1-6.
5. Ghosh A, Bhattacharya S, Sharma A. Bioenhancers: A review on natural compounds to enhance the bioavailability of drugs. J Drug Deliv Ther. 2019; 9(5):217-223. doi:10.22270/jddt. v9i5.2971.
6. Rasool M, Saleem M, Nisa M, et al. Role of curcumin as a bioenhancer for drugs: A review. J Drug Deliv Sci Technol. 2020; 60:101994. doi: 10.1016/j.jddst.2020.101994.
7. Kumar R, Sharma S, Gupta A, et al. Recent advances in the use of natural products as bioavailability enhancers. Eur J Med Chem. 2017; 143:124-140. doi: 10.1016/j.ejmech.2017.02.016.
8. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374(14):1356-1367. doi:10.1056/NEJMra1515442.
9. Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy-induced nausea and vomiting (CINV): Content and implementation in daily routine practice. Eur J Pharmacol. 2014; 722: 197-202. doi: 10.1016/j.ejphar.2013.09.073.
10. Siddiqui MJ, Rahman MA, Saeed MA, et al. Natural bioenhancers: A growing need for novel therapeutic strategies. J Ethnopharmacol. 2020; 246: 112230. doi: 10.1016/j.jep.2019.112230.
11. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: From bedside to bench and back. Biotechnol Adv. 2014; 32(6): 1053-1064. doi: 10.1016/j.biotechadv.2014.04.004.
12. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm. 2007; 4(6): 807-818. doi:10.1021/mp700113r.
13. Mohanty C, Das M, Sahoo SK. Emerging role of curcumin as a potent chemopreventive agent for prevention and treatment of cancer. Drug Discov Today. 2012; 17(13-14): 71-80. doi: 10.1016/j.drudis.2011.10.022.
14. Narade SB, Pore YV. Pharmacokinetic assessment of Natural Anticancer Berberine Chloride in presence and absence of some Herbal Bioenhancers in rabbit model. Research J. Pharm. and Tech. 2023; 16(11):5121-5129.
15. Narade SB, Pore YV, Optimization of ex vivo permeability characteristics of berberine in presence of quercetin using 32 full factorial design. Journal of Applied Pharmaceutical Science 2019; 9 (1):073-082.
16. Narade SB, Pore YV, Effect of co-administration of quercetin on goat intestinal permeability of berberine chloride. Int J Pharma Sci Res. 2019; 10 (8):3915-3919.
17. Narade SB, Pore YV, Assessment of permeability behavior of berberine chloride across goat intestinal membrane in presence of natural biopotentiator curcumin. Indian Drugs 2021; 58 (4): 23-27.
18. Narade SB, Pore YV. Optimization of goat intestinal permeability of berberine chloride in presence of natural bioenhancer piperine using 32 full factorial design. International Journal of Biology, Pharmacy and Allied Sciences. 2022, 11(10): 4758-4778.
19. Rathore R, Gupta AK, ParasharAK, Formulation and Evaluation of fast dissolving films of Granisetron Hydrochloride, Journal of Drug Delivery and Therapeutics. 2019; 9(2-A):36-38
20. Bustos, M.L. ∙ Zhao, Y. ∙ Chen, H. Polymorphisms in CYP1A1 and CYP3A5 genes contribute to the variability in granisetron clearance and exposure in pregnant women with nausea and vomiting. Pharmacotherapy. 2016; 36:1238-1244.
21. George B, Wen X, Jaimes EA, Joy MS, Aleksunes LM. In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs. International Journal of Molecular Sciences. 2021; 22(12):6439.
22. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V. and Limtrakul P.N.: Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol., 2002, 64(4) 573-82.
23. Volak L.P., Ghirmai S., Cashman J.R. and Court M.H.: Curcuminoids inhibit multiple human cytochromes P450 (CYP), UDP-glucuronosyltransferase (UGT), and sulfotransferase (SULT) enzymes, while piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos., 2008, 36(8) 1594–1605.
24. Zhang W., Tan T.M.C. and Lim L.Y.: Impact of Curcumin-Induced Changes in P-Glycoprotein and CYP3A Expression on the Pharmacokinetics of Peroral Celiprolol and Midazolam in Rats. Drug Metabolism and Disposition, 2007, 35 (1) 110-115.
25. Nakamura Y, Yoshimura H, Kato S, Nakamura Y, Yamamoto T, Kuroda Y, et al. Modulation of P-glycoprotein function by curcumin and its derivatives in human intestinal Caco-2 cells. Phytother Res. 2013;27(6):940-945.
26. Tzeng SH, Chen KF, Lin CC, Lu HT, Hsieh CL. The inhibitory effect of curcumin on CYP3A4 enzymes and its impact on the pharmacokinetics of celiprolol and midazolam in rats. J Nat Prod. 2015; 78(3): 232-238.
27. Sharma S, Kaur IP, Raza K, Malhotra M. Curcumin-based gastroretentive emulsomes for enhancing the bioavailability of drugs with poor water solubility. J Ethnopharmacol. 2016; 193: 112-120.
28. Sharma A, Gupta M. The impact of curcumin on the pharmacokinetics of drugs: A comprehensive review. Indian J Pharm Sci. 2017;79(5):684-691.
29. Oteiza PI, Erlejman AG, Verstraeten SV, Keen CL, Fraga CG. Curcumin and its protective effects against oxidative stress-induced alterations in membrane proteins and tight junctions. Mol Nutr Food Res. 2017;61(6):1600787.
30. Huang J, Bai Y, Liang H, Li Y, Duan Y, Lin D, et al. Concentration-dependent effects of curcumin on enhancing or inhibiting the permeability of P-glycoprotein substrates. Molecules. 2018; 23(7): 1806.
31. Kang Y, Lee SH, Lee SB, Park JS, Kim SE, Kim D-K. Curcumin inhibits the activation of hepatic stellate cells by downregulating P-glycoprotein. J Ethnopharmacol. 2013; 146(2): 562-569.
32. Teng L, Meng Q, Lu J, Mei Q, Liu Q, Ma H. Effects of curcumin on the pharmacokinetics of midazolam, a probe drug of cytochrome P450 3A, in rats. Drug Metab Dispos. 2015; 43(6): 820-827.
33. Zhang W, Li Y, Meng Q, Sun Y, Yan P, Chen Y. Curcumin modulates intestinal barrier function through tight junction proteins. Mol Nutr Food Res. 2016; 60(5): 1199-1209.
34. Srinivas M, Gupta AK, Iyer V, Gopal V, Rajesh V, Dhiman R. Modulation of gastrointestinal tract physiology by curcumin pre-treatment: impact on drug absorption. Phytomedicine. 2017; 24:11-19.
35. Patel K, Patel H, Panchal M, Patel V, Chanda S. Multi-day pre-treatment with curcumin enhances pharmacokinetic profile of bioenhanced drugs. Int J Pharm. 2018; 548(1): 105-113.
36. Lin X, Tang Y, Zhang L, Su Z, Luo X. Seven-day pre-treatment with curcumin enhances oral bioavailability of celiprolol in rats. Eur J Pharm Sci. 2019; 136:104950.
37. Humbe PV. Bioenhancers – a review. Res J Pharm Dosage Form Tech. 2015;7(4):274-84.
38. Tripathi K. Curcumin – the spice of life – I. Res J Pharmacogn Phytochem. 2009;1(3):153-61.
39. Shinde AD, Bhise SB. Optimization of pharmacokinetics by loading bioenhancer in optimized nasal mucoadhesive microspheres of insulin. Res J Pharm Tech. 2010; 3(2):613-8.
40. Vaisakh M. N., Anima Pandey. Assessment of curcumin release with different permeation enhancers. Research J. Pharm. and Tech. 2012; 5(3): 408-410.
41. Bhimanwar R, Kothapalli L, Khawshi A. Quercetin as a natural bioavailability modulator: an overview. Res J Pharm Tech. 2020; 13(4): 2043-50.
42. Wadhwa K, Rana AC, Mittal P, Banwala S, Sharma S. Insights on prospective role of gallic acid as a bioavailability enhancer. Res J Pharm Tech. 2023; 16(2): 983-8.
43. Patil SP, More SR, Thorat MS, Masule AA. Molecular docking, pharmacophore mapping, and virtual screening of potent human P-glycoprotein inhibitors. Int J Pharm Sci. 2024; 2(9): 1358-73. doi: 10.5281/zenodo.13851194.
44. Brahamdutt, Narwal S, Kumar A, Chaudhary M, Budhwar V. Formulation of eutectic mixture of curcumin with salicylic acid for improving its dissolution profile. Res J Pharm Tech. 2021; 14(4): 1875-9.
45. Alabdali AYM, Chinnappan S, Abd Razik BM, Mogana R, Khalivulla SI, Rahman H. Pharmacological activities of curcumin: an update. Res J Pharm Tech. 2022; 15(6): 2809-13.
46. Sweetha G, Sangeetha B, Prabhu S. A review on curcumin nanoparticles and its controlled delivery to treat degenerative diseases. Asian J Pharm Tech. 2013; 3(4): 218-22.
47. Masule AA, Murari VM. Utilization of stem cells for cancer treatment: a review. Asian J Pharm Res. 2023; 13(4): 269-76. doi: 10.52711/22315691.2023.00049.